Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226699 | 0.90 | MEN1 (0.45) | SMN1; SMN2NOTUMTSHRPOLBLMNA | |
| SCHEMBL30866830 | 0.76 | TSHR (0.59) | SMN1; SMN2TSHRLMNAKMT2AMEN1 | |
| SCHEMBL5261945 | 0.76 | TSHR (0.59) | SMN1; SMN2TSHRLMNAKMT2AMEN1 | |
| SCHEMBL28654768 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2NOTUMTSHRPOLBRECQL | |
| SCHEMBL1859866 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2NOTUMTSHRPOLBRECQL | |
| SCHEMBL16353530 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2NOTUMTSHRLMNAKMT2A | |
| SCHEMBL14625026 | 0.74 | NOTUM (0.50) | SMN1; SMN2NOTUMTSHRPOLBRECQL | |
| SCHEMBL9038764 | 0.73 | SMN1; SMN2 (0.49) | SMN1; SMN2NOTUMTSHRPOLBRECQL | |
| SCHEMBL1852381 | 0.73 | NOTUM (0.45) | SMN1; SMN2NOTUMTSHRPOLBLMNA | |
| SCHEMBL1716131 | 0.72 | SMN1; SMN2 (0.56) | SMN1; SMN2NOTUMTSHRPOLBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1778654-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | Crystalgenomics, Inc. (KR) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006006832-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | CRYSTALGENOMICS, INC. (KR) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | SMN1; SMN2 1998/4885NOTUM 239/4885TSHR 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.